Orthofix officer sells 2,312 shares for taxes

Orthofix Medical Inc. executive Lucas Vitale, listed as CP&BOO, reported selling a total of 2,312 shares of common stock in two open-market transactions on March 4 and March 5, 2026.

Rhea-AI Filing Summary

Orthofix Medical Inc. executive Lucas Vitale, listed as CP&BOO, reported selling a total of 2,312 shares of common stock in two open-market transactions on March 4 and March 5, 2026. The shares were sold at weighted average prices of $12.9163 and $12.5508 per share.

According to a footnote, these sales were made solely to satisfy tax withholding obligations tied to the settlement of restricted stock units under a pre-existing, committee-mandated sell-to-cover requirement, with no discretion exercised by Vitale. After these transactions, he held 164,718 shares and restricted stock units.

Insider Trade Summary

Net Seller: 2,312 shares

Net Sell 2 txns

Insider Vitale Lucas

Role CP&BOO

Sold 2,312 shs ($29K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,141	$12.5508	$14K
Sale	Common Stock	1,171	$12.9163	$15K

Holdings After Transaction: Common Stock — 164,718 shares (Direct)

Footnotes (4)

1. F1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
3. F3. Includes 138,173 previously reported restricted stock units.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Orthofix (OFIX) report for Lucas Vitale?

Orthofix reported that executive Lucas Vitale sold 2,312 common shares. The Form 4 shows two open-market sales on March 4 and March 5, 2026, executed to cover tax withholding obligations related to restricted stock unit settlements under a pre-approved sell-to-cover requirement.

At what prices did Lucas Vitale sell Orthofix (OFIX) shares?

Vitale’s reported weighted average sale prices were $12.9163 and $12.5508 per share. Footnotes note the March 4 trades occurred between $12.80 and $13.03, and the March 5 trades between $12.48 and $12.72, across multiple transactions within each range.

Why were Lucas Vitale’s Orthofix (OFIX) shares sold according to the Form 4?

The sales were made to satisfy tax withholding obligations on restricted stock units. A footnote explains they occurred under a pre-existing, Compensation and Talent Development Committee–mandated sell-to-cover requirement, and were executed without any discretionary decision by Vitale.

How many Orthofix (OFIX) shares and units does Lucas Vitale hold after these sales?

After the reported transactions, Vitale held 164,718 shares and restricted stock units. A footnote clarifies this total includes 138,173 previously reported restricted stock units, reflecting his remaining equity stake following the tax-related share sales.

What role does Lucas Vitale hold at Orthofix (OFIX) in this Form 4?

The Form 4 identifies Lucas Vitale as an officer with the title “CP&BOO.” He is not listed as a director or 10% owner in the filing, and the reported transactions involve his directly held common stock used for tax withholding obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:19 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitale Lucas

(Last) (First) (Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE TX 75056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CP&BOO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		1,171	D	$12.9163(2)	165,859(3)	D
Common Stock	03/05/2026		S(1)		1,141	D	$12.5508(4)	164,718(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

3. Includes 138,173 previously reported restricted stock units.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

	/s/ J. Andres Cedron, Attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.